281 related articles for article (PubMed ID: 17705569)
21. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
J Clin Pharmacol; 2007 Mar; 47(3):343-50. PubMed ID: 17322146
[TBL] [Abstract][Full Text] [Related]
22. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Mercadante S; Ferrera P; Arcuri E
Support Care Cancer; 2011 Mar; 19(3):435-8. PubMed ID: 20882391
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat.
Ashburn MA; Ogden LL; Zhang J; Love G; Basta SV
J Pain; 2003 Aug; 4(6):291-7. PubMed ID: 14622685
[TBL] [Abstract][Full Text] [Related]
24. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?
Moksnes K; Fredheim OM; Klepstad P; Kaasa S; Angelsen A; Nilsen T; Dale O
Eur J Clin Pharmacol; 2008 May; 64(5):497-502. PubMed ID: 18180911
[TBL] [Abstract][Full Text] [Related]
25. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
Slatkin NE; Xie F; Messina J; Segal TJ
J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
[TBL] [Abstract][Full Text] [Related]
28. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
Davies A; Kleeberg UR; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
Support Care Cancer; 2015 Jul; 23(7):2135-43. PubMed ID: 25556611
[TBL] [Abstract][Full Text] [Related]
29. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Mercadante S
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
[TBL] [Abstract][Full Text] [Related]
30. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers.
Vasisht N; Gever LN; Tagarro I; Finn AL
J Clin Pharmacol; 2010 Jul; 50(7):785-91. PubMed ID: 20150521
[TBL] [Abstract][Full Text] [Related]
32. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
[TBL] [Abstract][Full Text] [Related]
33. Fentanyl buccal tablets.
Webster LR
Expert Opin Investig Drugs; 2006 Nov; 15(11):1469-73. PubMed ID: 17040204
[TBL] [Abstract][Full Text] [Related]
34. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
Webster LR; Messina J; Xie F; Nalamachu S
J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
[TBL] [Abstract][Full Text] [Related]
35. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
Freise KJ; Newbound GC; Tudan C; Clark TP
J Vet Pharmacol Ther; 2012 Aug; 35 Suppl 2():27-33. PubMed ID: 22731773
[TBL] [Abstract][Full Text] [Related]
37. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects.
Nave R; Schmitt H; Popper L
Drug Deliv; 2013; 20(5):216-23. PubMed ID: 23650968
[TBL] [Abstract][Full Text] [Related]
38. Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study.
Chen C; Bujanover S; Gupta A
J Opioid Manag; 2015; 11(2):139-46. PubMed ID: 25901479
[TBL] [Abstract][Full Text] [Related]
39. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
40. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
Vasisht N; Gever LN; Tagarro I; Finn AL
Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
